Journal of Hepatology
Volume 50, Issue 6 , Pages 1280-1282 , June 2009

HALT-C in the final analysis: A molehill out of a mountain

References 

  1. Almasio P, Camma C, Di Marco V, Craxi A. Hepatitis B. In:  McDonald JWD, et al. editor. Evidence-based Gastroenterology and Hepatology. London: BMJ Books; 2004;p. 367–371
  2. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, et al. Sustained virological response to interferon-alpha is associated with improbe outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579–587
  3. Niederau C, Fischer R, Pürschel A, Stremmel W, Häussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 1996;110:1107–1119
  4. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008;359:2429–2441
  5. Poynard T, Moussali J, Ratziu V, Regimbeau C, Opolon P. Effects of interferon therapy in non responder patients with chronic hepatitis C. J Hepatol. 1999;31(Suppl 1):178–183
  6. Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology. 1999;117:1164–1172
  7. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials. 2004;25:472–492
  8. Afdhal NH, Levine R, Brown R, Freilich B, O’Brien M, Brass C. Colchicine versus peginterferon alpha 2b long term therapy: results of the 4 year COPILOT trial. J Hepatol. 2008;48(Suppl 2):S4
  9. Poynard T, Schiff E, Terg R, Moreno Otero R, Flamm S, Schmidt W, et al. Sustained viral response (SVR) is dependent on baseline characteristics in the retreatment of previous alfa Interferon/Ribavirin (I/R) nonresponders (NR): final results from the EPIC3 program. J Hepatol. 2008;48(Suppl 2):S369
  10. Cammà C, Giunta M, Andreone P, Craxı` A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol. 2001;34:593–602
  11. Shiffman ML, Morishima C, Lindsay KL, Hoefs JC, Dienstag JL, Szabo G, et al. Suppression of serum HCV RNA levels during maintenance PEGINTERFERON (PEGIFN) alfa-2a therapy and clinical outcomes in the HALT-C trial. J Hepatol. 2008;48(Suppl 2):S62

☆ The author declares that he has received no funding from industries and has no conflict of interest with respect to this manuscript.

PII: S0168-8278(09)00153-6

doi: 10.1016/j.jhep.2009.03.001

Journal of Hepatology
Volume 50, Issue 6 , Pages 1280-1282 , June 2009

Article Tools